---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-22-002398"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2022-06-17T23:59:59+00:00"
generated_at: "2026-06-25T00:53:48.341859+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Entera Bio President of R&D & Director resigns under separation deal with cash and option benefits

## Summary
- Dr. Phillip Schwartz resigns as President of R&D (effective July 21, 2022) and from Board (immediate); no disagreement.
- Cash separation payment of ~$155,900 plus ~$213,952 in accrued benefits; also fully accelerated 100,000 option shares subject to shareholder approval.
- Proposed consulting agreement for business development services with 14-day termination notice.
- Schwartz agrees to non-disparagement, mutual release, and voting/standstill restrictions until after 2023 AGM.

## SEC filing metadata
- accession: 0001178913-22-002398
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2022-06-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891322002398/0001178913-22-002398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891322002398/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-22-002398
- JSON: https://secwatch.observer/filing/0001178913-22-002398.json
- Plain text: https://secwatch.observer/filing/0001178913-22-002398.txt

## Key facts
- Executive change
  Phillip Schwartz resigned as Director at Entera Bio Ltd..
  - Action: resigned
  - Role: Director
  source text: would resign from the Company’s Board of Directors (the “Board”), effective as of the Effective Date
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638097/000117891322002398/0001178913-22-002398-index.htm
- Executive change
  Phillip Schwartz resigned as President of Research & Development at Entera Bio Ltd..
  - Action: resigned
  - Role: President of Research & Development
  source text: Dr. Schwartz would resign from his position as the Company’s President of R&D, effective July 21, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638097/000117891322002398/0001178913-22-002398-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.